Anish Suri has been appointed chief scientific officer of preclinical-stage immunotherapy developer Cue Biopharma (NASDAQ: CUE). Suri most recently worked in Belgium at Janssen Immunosciences, where he was senior director. Cambridge, MA-based Cue, which went public at the end of 2017, is developing immunotherapies to treat cancers and autoimmune diseases.
UNDERWRITERS AND PARTNERS